Compare Mesoblast Limited (MESO) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Norfolk Southern Corporation — how do they compare? Mesoblast Limited trades at $16.32 (market cap $2.17B), while Norfolk Southern Corporation trades at $334.25 (market cap $75.23B). The key difference: Norfolk Southern Corporation is far larger — about 34.7× Mesoblast Limited's market cap, and Norfolk Southern Corporation pays a 1.61% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | NSC | |
|---|---|---|
Market Cap | $2.17B | $75.23B |
Sector | Technology | Technology |
52-Week High | $20.96 | $340.16 |
52-Week Low | $12.88 | $272.35 |
Enterprise Value | $2.17B | $90.99B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Norfolk Southern (NSC) trades at $334.97, down 1.53% today, with a bullish technical outlook from moving averages but overbought RSI signals. The company shows strong profitability with a 21.91% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights the pending merger with Union Pacific and upcoming Q2 2026 earnings on July 23, 2026.
The stock offers a moderate upside to the $344.40 consensus price target, supported by earnings momentum and cost controls, but faces risks from regulatory scrutiny of the merger and rich valuations. Investor sentiment is mixed amid merger uncertainties and high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
